|
Median follow-up (months)
|
59.3 (16.5-82.6)
|
|
Gland volume at implant (cc)
| |
|
mean
|
41
|
|
median
|
39 (16–107)
|
|
Age at treatment (years)
| |
|
mean
|
67.7
|
|
median
|
68.4 (44.1-82.2)
|
|
Pre-treatment PSA (ng/ml)
| |
|
mean
|
7.1
|
|
median
|
6.4 (2.0-34.1)
|
| |
n (%)
|
|
Stage
| |
|
T1b-c
|
129 (36.7%)
|
|
T2a
|
113 (32.1%)
|
|
T2b
|
55 (15.6%)
|
|
T2c
|
53 (15.0%)
|
|
T3a
|
1 (0.2%)
|
|
Gleason score
| |
|
≤ 6
|
281 (80.0%)
|
|
7
|
62 (17.6%)
|
|
> 7
|
8 (2.2%)
|
|
Pre-treatment PSA (ng/ml)
| |
|
≤ 10
|
324 (92.3%)
|
|
11-20
|
23 (6.5%)
|
|
> 20
|
4 (1.1%)
|
|
Age at treatment (years)
| |
|
< 60
|
51 (14.5%)
|
|
60-69
|
169 (48.1%)
|
|
≥ 70
|
131 (37.3%)
|
|
Androgen deprivation therapy
|
70 (19.9%)
|
|
Risk group
| |
|
Low
|
196 (55.8%)
|
|
Intermediate
|
81 (23.0%)
|
|
High
|
74 (21.0%)
|
